Human Vaccines & Immunotherapeutics · 2018 · 131 citations · 211 references
Life SciencesImmunologyPharmacologyAutoimmunityClinical ImmunologyMonoclonal AntibodiesB Cell BiologyB Cell PharmacologyB Cell RegulationHumoral ImmunityMonoclonal Antibody TherapyTherapeutic Monoclonal AntibodiesAnti-cd20 Antibody TherapyAnti-cd20 TherapyB Cell-targeted ImmunotherapyB-cell Malignancy TherapyB-cell Targeted TherapyMonoclonal Antibody TherapeuticsRituximab-based TherapyTherapeutic Target Identification
Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have revolutionised the treatment of B cell hematological malignancies and have become a cornerstone of modern gold-standard practice. Additionally, the potent efficacy of these agents in depleting the B cell compartment has been used in the management of a broad array of autoimmune diseases. Multiple iterations of these agents have been investigated and are routinely used in clinical practice. In this review, we will discuss the physiology of CD20 and its attractiveness as a therapeutic target, as well as the pharmacology, pre-clinical and clinical data for the major anti-CD20 monoclonal antibodies: rituximab, obinutuzumab and ofatumumab.
211
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Raphael Clynes, Terri L. Towers, Leonard G. Presta et al. · Nature Medicine · 2000 · 2.7K citations
Medicine, Cancer Biology, Oncology +15
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
John H. Stone, Peter A. Merkel, Robert Spiera et al. · New England Journal of Medicine · 2010 · 2.7K citations · Full text